Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

Lancet

Volumn 360, Issue 9332, 2002, Pages 516-520

  Anderson, Lisa J ^a   Wonke, Beatrix ^c   Prescott, Emma ^c   Holden, Sally ^b   Walker, J Malcolm ^b   Pennell, Dudley J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON;

ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; IRON OVERLOAD; LONG TERM CARE; MALE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

EID: 0037125595     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09740-4     Document Type: Article

References (30)

1. Zurlo M.G., De Stefano P., Borgna-Pignatti C., et al. Survival and causes of death in thalassaemia major. Lancet. 2:1989;27-30.
2. Modell B., Khan M., Darlison M. Survival in beta thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 355:2000;2051-2052.
3. Weatherall D.J., Pippard M.J., Callender S.T. Iron loading in thalassemia: five years with the pump. N Engl J Med. 308:1983;456-458.
4. Olivieri N.F., Brittenham G.M., Matsui D., et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 332:1995;918-922.
5. Kontoghiorghes G.J., Bartlett A.N., Hoffbrand A.V., et al. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1): 1, iron chelation and metabolic studies. Br J Haematol. 76:1990;295-300.
6. Agarwal M.B., Gupte S.S., Viswanathan C., et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 82:1992;460-466.
7. Olivieri N.F., Brittenham G.M., McLaren C.E., et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 339:1998;417-423.
8. Hoffbrand A.V., AL-Refaie F., Davis B., et al. Long term trial of deferiprone in 51 transfusion dependent iron overloaded patients. Blood. 91:1998;295-300.
9. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 22:2001;2171-2179.
10. Bellenger N.G., Francis J.M., Davies C.L., Coats A., Pennell D.J. Establishment and performance of a magnetic resonance cardiac function clinic. J Cardiovasc Magn Reson. 2:2000;15-22.
11. Bellenger N.G., Davies L.C., Francis J.M., Coats A.J.S., Pennell D.J. Reduction in sample size for studies of remodelling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2:2000;271-278.
12. Lorenz C.H., Walker E.S., Morgan V.L., et al. Normal human right and left ventricular mass, systolic function and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson. 1:1999;7-21.
13. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. BMJ. 2:1962;1577-1580.
14. Barry M., Flynn D., Letsky E., Risdon R.A. Long term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress. BMJ. 2:1974;16-20.
15. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of desferrioxamine in preventing complication of iron overload in patients with thalassaemia major. N Engl J Med. 331:1994;567.
16. Modell B., Letsky E.A., Flynn D.M., Peto R., Weatherall D.J. Survival and desferrioxamine in thalassaemia major. BMJ. 284:1982;1081.
17. Wolfe L., Olivieri N., Sallan D., et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassaemia major. N Engl J Med. 312:1985;1600-1603.
18. Karnon J., Zeuner D., Brown J., Ades A.E., Wonke B., Modell B. Lifetime treatment costs of beta-thalassaemia major. Clin Lab Haematol. 21:1999;377-385.
19. Arden G.B., Wonke B., Kennedy C., Huehns E.R. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 68:1984;873-877.
20. Olivieri N.F., Buncic J.R., Chew E., et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 314:1986;869-873.
21. Brill P.W., Winchester P., Giardina P.J., Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol. 156:1991;561-565.
22. De Virgiliis S., Congia M., Frau F., et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr. 113:1988;661-669.
23. Porter J.B. A risk-benefit assessment of iron-chelation therapy. Drug Saf. 17:1997;407-421.
24. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 331:1994;574-578.
25. Tondury P., Kontoghiorghes G.J., Ridolfi-Luthy A., et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol. 76:1990;550-553.
26. Al-Refaie F.N., Wonke B., Hoffbrand A.V., Wickens D.G., Nortey P., Kontoghiorghes G.J. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood. 80:1992;593-599.
27. Anderson L., Porter J.B., Wonke B., et al. Cardiac iron deposition is not predicted by conventional markers of iron overload in homozygous beta-thalassaemia. Blood. 96:(suppl I):2000;606a. abstr.
28. Shalev O., Repka T., Goldfarb A., et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood. 86:1995;2008-2013.
29. de Franceschi L., Shalev O., Piga A., et al. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med. 133:1999;64-69.
30. Porter JB. Development of Primary Hepatocyte Cultures for the Preclinical Evaluation of Iron Chelators. MD Thesis, University of Cambridge, 1999.